TCR pi­o­neer Im­muno­core scores a first with a land­mark PhI­II snap­shot on over­all sur­vival for a rare melanoma

Bahi­ja Jal­lal’s crew at TCR pi­o­neer Im­muno­core says they have nailed down a promis­ing set of piv­otal da­ta for their lead drug in a front­line set­ting for a sol­id tu­mor. And they are fram­ing this ear­ly in­ter­im read­out as the con­vinc­ing snap­shot they need to prove that their plat­form can de­liv­er on a string of break­through ther­a­pies now in the clin­ic or planned for it.

In ad­vance of the Mon­day an­nounce­ment, Jal­lal and R&D chief David Berman took some time to walk me through the first round of Phase III da­ta for their lead TCR de­signed to treat rare, front­line cas­es of metasta­t­ic uveal melanoma that come with a grim set of sur­vival ex­pec­ta­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER